Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses the promise of immuno-oncology in the treatment of patients with mesothelioma. In second line, nivolumab and pembrolizumab are…
Hui-Zi Chen, MD, PhD, assistant professor in the Department of Internal Medicine, Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center – James, discusses the…
Ragini R. Kudchadkar, MD, associate professor Department of Hematology and Medical Oncology, associate director of Hematology and Medical Oncology Fellowship Program – Clinical/Service at Emory University School of…
Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, senior physician at Dana-Farber Cancer Institute, and Jerome and Nancy…
In this interview, Yousef Zakharia, MD, shares thoughts on the topic of expanding acute myeloid leukemia (AML) treatment. Dr. Zakharia discusses up-to-date AML treatments from combination trials such…
Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, explains the results of a phase 1 trial…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase…
Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses maintenance chemotherapy…
Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow…
Jae H. Park, MD, hematologic oncologist and attending physician at the Leukemia Service and Cellular Therapeutics Center of Memorial Sloan Kettering Cancer Center, discusses the future of chimeric…
